EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Testing the external validity of the standard vs. extended lymphadenectomy for muscle invasive bladder cancer trial in a north American cohort

Bertini Alessandro, Alex Stephens, Finocchiaro Alessio, Viganò Silvia, Perri Antonio, Lughezzani Giovanni, Buffi Nicolò, Ficarra Vincenzo, Briganti Alberto, Salonia Andrea, Francesco Montorsi, Akshay Sood, Craig Rogers, Firas Abdollah, Alessandro Bertini

Bladder · 2026

DOI: 10.14440/bladder.026040009 ↗
AbstractBibliografische Angaben

Abstract

The SWOG S1011 randomized controlled trial provided level-one evidence demonstrating no significant advantage of extended lymph node dissection (ELND) over standard lymph node dissection (SLND) in terms of recurrence-free and overall survival for patients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy (RC). However, the generalizability of these findings to real-world North American practice remains unclear. To assess the external validity of this trial, we used data from the National Cancer Database (NCDB) to simulate the original trial inclusion criteria, identifying patients with clinical T2–4a, N0–2 bladder cancer who underwent RC with LND between 2010 and 2022. Sociodemographic and clinical characteristics of the NCDB cohort were compared with those reported in the SWOG S1011 trial. Although the original trial excluded robot-assisted RC, both open and robotic approaches were included in this analysis and evaluated separately. Overall, 26,183 patients underwent RC, of whom 16,814 (64.3%) received open RC and 9,369 (35.7%) robot-assisted RC. No clinically meaningful differences were observed between cohorts in terms of age, sex, or self-reported race. In contrast, patients enrolled in the trial were more likely to present with cT3–4a disease and to receive neoadjuvant systemic therapy, resulting in a lower proportion of pT≥2 N0 tumors compared with patients treated in routine practice. Moreover, the median number of lymph nodes removed in both the SLND and ELND trial arms was substantially higher than that observed in the NCDB open and robotic RC cohorts. These findings suggest that while the SWOG S1011 trial provides robust evidence against an oncological benefit of ELND over SLND in MIBC, its external validity is only partially supported, and differences from contemporary real-world practice may limit the generalizability of its conclusions.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →